CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

Study Overview
=================
Brief Summary
-----------------
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell lymphoma.

Detailed Description
-----------------
This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell lymphoma. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-cell lymphoma.

Official Title
-----------------
CD19/CD20 Dual-CAR-T for Patients With B-cell Lymphoma

Conditions
-----------------
B-cell Lymphoma

Intervention / Treatment
-----------------
* Biological: CD19/CD20 Dual-CAR-T cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Relapsed and refractory B-cell lymphoma with: Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed after autologous or allogeneic hematopoietic stem cell transplantation (ASCT); Patients must have evaluable evidence of disease, including minimal residual disease (MRD); Double positive expression of CD19 / CD20 in B cells; Ages 1 to 80 years, including boundary values; ECOG score 0-3 points; Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside; Patients who voluntarily sign informed consent and are willing to comply with treatment plans. Exclusion Criteria: patients with organ failure: Heart: NYHA heart function grade IV; Liver: Grade C that achieves Child-Turcotte liver function grading; Kidney: kidney failure and uremia; Lung: symptoms of respiratory failure; Brain: a person with a disability; Active infections that are difficult to control; Human immunodeficiency virus (HIV) positive; Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min; GVHD ≥ 2 or anti-GVHD treatment; intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; pregnant or lactating women; The patient does not agree to use effective contraception during the treatment period and for the next 3 months; Patients who participate in other clinical studies at the same time; The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CD19/CD20 Dual-CAR-T cells<br>CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for at least 2 days before infusion. | Biological: CD19/CD20 Dual-CAR-T cells<br>* CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of participants with adverse events. |  | 6 months | 
| Objective remission rate(ORR) | The percentage of participants who achieved complete remission (CR) and partial remission over all participants. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse-Free Survival(RFS ) |  | 6 months | 
| Overall-Survival(OS) |  | 6 months | 
| Persistence of CAR-T cells in vivo |  | 6 months |